Insights
Search Results
Client Highlights
2.06.26
Wilson Sonsini Advises PacBio on Sale of Short-Read DNA Sequencing Assets
On February 2, 2026, PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received approximately $50 million in cash proceeds from the transaction. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
Client Highlights
12.18.25
Firm Advises Culture Biosciences on Series C Financing Round
On December 16, 2025, Culture Biosciences, a leader in cloud-based biomanufacturing, announced the successful close of its Series C fundraising round led by existing investors including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox, reflecting strong conviction among current shareholders in Culture’s trajectory and long-term strategy. Wilson Sonsini Goodrich & Rosati advised Culture on the transaction.
The Series C financing will accelerate the commercial expansion of Culture’s next-generation hardware product, the Stratyx 250, as well as fuel continued development of the company’s AI-powered Console software ecosystem. The Stratyx 250 system is engineered to provide scalable, automated, and digitally connected bioprocess capacity designed for modern biologics, cell therapy, and advanced bioprocess development needs. In parallel, Culture will expand the AI-enabled capabilities of its Console software platform, including advanced data integration, predictive modeling, and automated analysis tools intended to streamline development cycles and enhance process decision-making for customers.
The Wilson Sonsini team that advised Culture on the financing included Andrew Hoffman, Terence Desouza, Utsav Lall, Kate Kirkpatrick, Michael Murrietta, and Casey Hepburn.
The Series C financing will accelerate the commercial expansion of Culture’s next-generation hardware product, the Stratyx 250, as well as fuel continued development of the company’s AI-powered Console software ecosystem. The Stratyx 250 system is engineered to provide scalable, automated, and digitally connected bioprocess capacity designed for modern biologics, cell therapy, and advanced bioprocess development needs. In parallel, Culture will expand the AI-enabled capabilities of its Console software platform, including advanced data integration, predictive modeling, and automated analysis tools intended to streamline development cycles and enhance process decision-making for customers.
The Wilson Sonsini team that advised Culture on the financing included Andrew Hoffman, Terence Desouza, Utsav Lall, Kate Kirkpatrick, Michael Murrietta, and Casey Hepburn.
Client Highlights
11.06.25
Wilson Sonsini Advises EVERY on $55 Million Series D
On November 4, 2025, The EVERY Company, a biotechnology leader pioneering precision fermentation for highly functional proteins, announced the successful close of its $55 million in Series D financing. The round was led by McWin Capital Partners, through the McWin Food Tech Fund, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, SOSV, and more. The proceeds from the Series D will be used to expand manufacturing capacity, move to profitability, and further expand its reach across the $270 billion egg market – particularly in the high-volume bakery segment. Wilson Sonsini Goodrich & Rosati advised EVERY on the transaction.
Client Highlights
12.10.24
Wilson Sonsini Advises Initial Purchasers in Rule 144A Offering of $1.4 Billion of BILL Convertible Senior Notes
On December 6, 2024, BILL Holdings announced the successful completion of an offering of $1.4 billion aggregate principal amount of 0% convertible senior notes due 2030 in a Rule 144A offering. The offering amount included the exercise in full of the option that BILL had granted to the initial purchasers to purchase up to an additional $150 million of notes.
Client Highlights
11.08.24
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange
On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio), a leading developer of high-quality, highly accurate sequencing solutions, announced that it entered into a privately negotiated exchange agreement with a holder of PacBio’s remaining outstanding 1.50 percent convertible senior notes due 2028, pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50 percent Convertible Senior Notes due 2029, (ii) issue 20,451,570 shares of PacBio’s common stock, and (iii) make a cash payment in the amount of $50 million in exchange for $459 million principal amount of the 2028 Notes. The exchange transaction is expected to close on or about November 21, 2024, subject to customary closing conditions.
News Articles
8.08.24
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Client Highlights
6.18.24
Wilson Sonsini Advises Learn to Win on $30 Million Series A Funding
On June 12, 2024, Learn to Win, a leading provider of personalized, predictive, and secure enterprise training software, announced it has raised an oversubscribed $30 million in Series A funding led by the Westly Group, with follow-on participation from Norwest Venture Partners and Pear VC. This funding accelerates the company's progress to scale its modern training platform that redefines the way people learn essential information in high-stakes environments.
Client Highlights
2.05.24
Wilson Sonsini Advises ArteraAI on $20 Million Funding
On February 1, 2024, ArteraAI, developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced it has secured an additional $20 million in capital fueled by several prominent large investment funds. Less than a year ago, ArteraAI emerged from stealth mode with an initial funding of $90 million. Since then, the company has made significant strides, obtaining a Medicare payment rate, growing distribution, and establishing a solid foundation for international expansion through strategic global partnerships to continue its research.
Client Highlights
10.06.23
Firm Advises Spark I Acquisition Corporation on $100 Million IPO
On October 5, 2023, Spark I Acquisition Corporation (the “Company”), a special purpose acquisition company, announced the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market and trade under the ticker symbol "SPKLU" beginning on October 6, 2023. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. After the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "SPKL" and "SPKLW," respectively. Wilson Sonsini Goodrich & Rosati is advising the Company on the transaction.
Client Highlights
8.03.23
Wilson Sonsini Advises PacBio on Apton Biosystems Acquisition
On August 2, 2023, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Apton Biosystems, Inc. (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell. Wilson Sonsini Goodrich & Rosati is representing PacBio in the transaction.
News Articles
8.01.23
Wilson Sonsini Practices and Attorneys Recognized in 2023 IFLR1000 Guide
In the recent 2023 edition of its annual guide, the IFLR1000 recognized numerous Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Client Highlights
6.26.23
Wilson Sonsini Advises PacBio on $441 Million Senior Notes Offering
On June 26, 2023, Pacific Biosciences of California, Inc. (PacBio) announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50 percent convertible senior notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375 percent convertible senior notes due 2030 in exchange for $441 million principal amount of the 2028 notes (the Exchange Transaction), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about June 30, 2023, subject to customary closing conditions.